-Hindustan Times With little transparency on how such deaths are investigated, and new rules relaxing how clinical trials are conducted in India, this data could be a poor estimate, said experts. Mumbai: At least 1,100 people who took part in clinical trials over the past four years have died, and 88 of these deaths were caused by direct side effects of the trials, the health ministry told the Rajya Sabha last week. But,...

-The Times of India NEW DELHI: To promote low-cost generic medicines, the government’s top drug regulatory board has allowed Jan Aushadhi Kendras — which are like fair price shops for medicines under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana — to substitute doctor’s prescription with a generic brand. On Thursday, the Drugs Technical Advisory Board cleared a proposal to amend a rule under the drugs law. “This proposal asking permission for chemists to...

-Deccan Chronicle Ayush ministry states that experience and evidence of effectiveness of these drugs is based on textual rationale and published in literature. Hyderabad: Fraudsters would flourish if patented or proprietary Ayruvedic, Siddha and Unani products are given licence without insisting on safety trials, industry experts and medical professionals have stated. The Centre has issued drug regulators in states a directive to issue licenses to patented and proprietary products of Ayurvedic, Siddha and...

-Livemint.com WHO says the Indian govt should ‘reconsider’ the compensation clause because an approval to the rules in the current form would affect the conduct of clinical trials in India New Delhi: The World Health Organization (WHO) has told the central government that the United Nations (UN) agency’s work with India would be “hampered” and drug companies driven away if the government goes ahead with stringent draft rules for compensation in case...

-The Times of India NEW DELHI: In a move to ensure efficacy of medicines sold in India, the drug regulator has made it mandatory for companies to include Indian patients in global clinical trials if they want to market in India a new drug developed outside the country. The decision was taken in a recent technical committee meeting, headed by director general of health services Jagdish Prasad. The committee, which was formed...